2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
700
Breast Neoplasms
630
Neoplasms
583
Leukemia, Myeloid, Acute
481
Colorectal Neoplasms
457
Multiple Myeloma
444
Melanoma
426
Prostatic Neoplasms
383
Neoplasm Metastasis
374
Pancreatic Neoplasms
364
Recurrence
350
Lymphoma
340
Ovarian Neoplasms
325
Lung Neoplasms
298
Lymphoma, Non-Hodgkin
295
Leukemia
287
Glioblastoma
276
Precursor Cell Lymphoblastic Leukemia-Lymphoma
249
Stomach Neoplasms
246
Leukemia, Lymphocytic, Chronic, B-Cell
235
Carcinoma, Hepatocellular
231
Squamous Cell Carcinoma of Head and Neck
220
Lymphoma, Large B-Cell, Diffuse
217
Myelodysplastic Syndromes
212
Carcinoma, Renal Cell
210
Lymphoma, Follicular
183
Head and Neck Neoplasms
172
Brain Neoplasms
169
Lymphoma, Mantle-Cell
167
Triple Negative Breast Neoplasms
166
Interventions
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Triple Negative Locally Advanced Non-resectable Breast Cancer
×
Clear all
NCT06827613
2025-09-24
START-002
Marengo Therapeutics, Inc.
Phase 1/2
Recruiting
50 enrolled